Literature DB >> 3428341

Absence of a clinically significant interaction between theophylline and furosemide.

U A Jänicke1, B Krüdewagen, A Schulz, U Gundert-Remy.   

Abstract

In new of previous contradictory results, the possible interaction between the loop diuretic furosemide and theophylline was re-evaluated in 12 healthy volunteers with a steady-state plasma theophylline level. Two doses of furosemide 20 mg at a 4 h interval did not influence the steady-state plasma concentration of theophylline despite causing a moderate diuresis. Urinary recovery of theophylline and its metabolites amounted to 106 +/- 21% of the dose without furosemide and 96 +/- 19% of the dose with furosemide, demonstrating that there was no influence on the enteral absorption of theophylline of the furosemide treatment. After the first dose of furosemide the fractional renal clearance (CLR1) of theophylline (fractional = hourly sampling period) changed in parallel with the urinary flow rate, without a significant difference between treatment with and without furosemide. After the second dose of furosemide, CLR1 was increased in the first hour and then it declined to levels far lower than the control value. This unexpected result could explain the unchanged plasma concentration of theophylline during furosemide treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428341     DOI: 10.1007/BF00544241

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Clinical experience with theophylline. Relarionships between dosage, serum concentration, and toxicity.

Authors:  M H Jacobs; R M Senior; G Kessler
Journal:  JAMA       Date:  1976-05-03       Impact factor: 56.272

3.  Binding of theophylline and its metabolites to human plasma proteins.

Authors:  U Gundert-Remy; R Hildebrandt
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

4.  Theophylline-furosemide inactivation?

Authors:  J W Toback; M E Gilman
Journal:  Pediatrics       Date:  1983-01       Impact factor: 7.124

5.  Theophylline--furosemide interaction?

Authors:  R S Nakagawa
Journal:  Am J Hosp Pharm       Date:  1982-02

Review 6.  Pharmacokinetic drug interactions with theophylline.

Authors:  J H Jonkman; R A Upton
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

7.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.

Authors:  M M Hammarlund; L K Paalzow; B Odlind
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Urine flow-dependence of theophylline renal clearance in man.

Authors:  D D Tang-Liu; T N Tozer; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

9.  Effect of intravenous furosemide on serum theophylline concentration.

Authors:  P F Conlon; G R Grambau; C E Johnson; J G Weg
Journal:  Am J Hosp Pharm       Date:  1981-09

10.  Blunting of furosemide diuresis by aspirin in man.

Authors:  E Bartoli; S Arras; R Faedda; G Soggia; A Satta; N A Olmeo
Journal:  J Clin Pharmacol       Date:  1980-07       Impact factor: 3.126

View more
  3 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 2.  The diuretic effect of adding aminophylline or theophylline to furosemide in pediatric populations: a systematic review.

Authors:  Paul Van Siang Lian Mang; Jun Chuen Hui; Rachel Si Jing Tan; M Shahnaz Hasan; Yao Mun Choo; Mohammed F Abosamak; Ka Ting Ng
Journal:  Eur J Pediatr       Date:  2022-10-17       Impact factor: 3.860

Review 3.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.